Sinusitis Treatment Market Revenue to Attain USD 3.99 Bn by 2033

05 Nov 2024

Share :

Table of Content

1. Sinusitis Treatment Revenue and Trends 2. Market Overview  3. Report Highlights of the Sinusitis Treatment Market 4. Sinusitis Treatment Market Trends 5. Regional Snapshot 6. Sinusitis Treatment Market Coverage 7. Market News

Sinusitis Treatment Revenue and Trends

The global sinusitis treatment market revenue reached USD 2.40 billion in 2024 and is predicted to attain around USD 3.99 billion by 2033 with a CAGR of 5.82%. The demand for over-the-counter medicines and treatments, like nasal corticosteroids and nasal sprays, is increasing, which is the key factor driving the market growth.

Market Overview 

Sinusitis is a medical disorder that has a harmful effect on the majority population in the world. The condition can be caused by simple climatic factors like smoke, animal dander, dust, and polluted air. Sinusitis is also characterized by inflammation of the sinus layer caused by irritants, viruses, allergens, bacteria, and microbes. The infected patient complains of facial pain, congestion, postnasal drip, and headache. Viral sinusitis is much easier to treat, and patients can quickly recover without antibiotics.

Report Highlights of the Sinusitis Treatment Market

• By type, the acute sinusitis segment dominated the market in 2023. The dominance of the segment can be attributed to the growing introduction of biologics like omalizumab etc.
• By type, the chronic segment is estimated to grow significantly over the forecast period. The growth of the segment can be linked to the increasing prevalence of chronic Hay sinusitis in the majority of the population in the world.
• By route of administration, the nasal segment led the sinusitis treatment market in 2023 by holding the largest market share. This is because drug administration through nasal root absorbed more drugs to exert local or systemic therapeutic effects.
• By route of administration, the oral segment held a significant share in 2023. This is because oral administration is convenient and cost-effective. This route is also the most commonly used drug administration route.
• By treatment, in 2023, the analgesic segment dominated the sinusitis treatment market holding share. The dominance of the segment can be credited to the rising consumption of analgesics which relieve the pain caused by pressure buildup in the sinus cavities.

Sinusitis Treatment Market Trends

Rising Prevalence of Sinusitis

The prevalence of sinus infections among adults and children is increasing dramatically. The factors responsible for this are compromised immunity, respiratory tract infections, and nasal polyps. Additionally, Sinusitis can be triggered in children by utilizing a daycare, a pacifier, and second-hand contact with smoke. Hence the rising occurrence of sinusitis is fuelling the sinusitis treatment market growth.

Enhanced intra-nasal drug delivery 

The high prevalence of sinusitis across the globe is generating beneficial revenue opportunities for market players. Key market players are taking benefits from innovations launched by drug researchers. However, new innovative devices that allow individuals to treat themselves at home decrease the symptoms of sinusitis in primary stages. Which in turn improves the life quality of patients.

• In November 2023, Intersect ENT launched its Sinuva Sinus Implant, a new way to treat nasal polyp disease in adult patients who have had previous sinus surgery.  The Menlo Park, CA-based company said nearly 635,000 Americans have gone through these surgeries and are looking for treatments to cure side effects.

Increasing approval from regulatory bodies

Growing recommendation from government regulatory bodies for approval of emerging drugs utilized in the treatment of nasal polyps is anticipated to boost the market growth. Furthermore, investors are also investing a large amount in innovative nasal spray designs, which is a fast-paced phenomenon in the global market.

Regional Snapshot

North America dominated the sinusitis treatment market in 2023. The dominance of the region can be credited to the rising pervasiveness of viral and bacterial infections. Coupled with the increasing incidence of rhinosinusitis in the region. Furthermore, major players in the market are emphasizing the development of innovative drug products for sinusitis because of current innovations and advanced technology.

Asia Pacific is expected to grow at the fastest rate over the projected period. The growth of the region can be attributed to the high prevalence of sinusitis in the region. However, the emerging economies in the region, such as India and China, have the world's worst air quality, which can lead to rapid growth in respiratory disorders along with the growth in urbanization.

Sinusitis Treatment Market Coverage

Market News

• In May 2024, Optinose, a pharmaceutical leader emphasized on patients treated by ear, nose, and throat (ENT) and allergy specialists, declared that it has entered into agreements for the sale of approximately $55 million of its common stock and pre-funded common stock warrants to a group of existing and new institutional investors in a registered direct offering.
• In May 2022, Medtronic plc, a global leader in healthcare technology, announced that it had completed the acquisition of Intersect ENT, strengthening the company's comprehensive ear, nose, and throat (ENT) portfolio with advanced products used in sinus procedures to enhance post-operative outcomes and to treat nasal polyps.

Market Segmentation

By Type

• Chronic Sinusitis
• Acute Sinusitis
• Sub-Acute Sinusitis

By Route of Administration

• Nasal
• Oral
• Injectable
• Topical

By Treatment

• Antibiotic
• Analgesic
• Anti-inflammatory
• Expectorants

Get this report to explore global market size, share, CAGR and trends, featuring detailed segmental analysis and an insightful competitive landscape overview@ https://www.precedenceresearch.com/checkout/5172

You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com | +1 804 441 9344